Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1124 - The evolution of value with filgrastim in oncology

Date

10 Sep 2017

Session

Poster display session

Presenters

Paul Cornes

Citation

Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375

Authors

P. Cornes1, A. Krendyukov2

Author affiliations

  • 1 (comparative Outcomes Group), Comparative Outcomes Group, BS2 8DA - Bristol/GB
  • 2 (hexal Ag), Hexal AG, Holzkirchen/DE
More

Resources

Abstract 1124

Background

The value of drugs will evolve over time as new evidence for risks and benefits emerge and the price of a drug changes.

Methods

A NICE Evidence Search on March 1, 2017 revealed 25 systematic reviews and 55 economic evaluations of filgrastim.1

Results

Initial Health Technology Assessments (HTA) suggested low value due to high drug cost and no evidence for significant gain in Overall Survival (OS). More recent metanalyses of placebo-controlled randomized trial data show absolute OS gains of 3.2% (95% CI:2.1—4.2%) from filgrastim support of cytotoxic chemotherapy2 and falling costs due to biosimilar competition.

Conclusions

Physicians and payers need to be aware that HTA decisions need constant re-evaluation, especially following the launch of biosimilar alternatives. This explains the first inclusion of filgrastim in the WHO essential Drug List for cancer more than 20 years after its original approval in 1991,3 and demonstrates the power of biosimilar medicines in transforming healthcare. References [1] NICE Database search “filgrastim”, performed March 1, 2017. URL: https://www.evidence.nhs.uk/search?q=filgrastim. [2] Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Annals of Oncology. 2013;24(10):2475-2484. doi:10.1093/annonc/mdt226. [3] WHO Model Lists of Essential Medicines, 19th Edition Reviewed November 2015.URL: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed March 1, 2017.

Clinical trial identification

N/A

Legal entity responsible for the study

N/A

Funding

None

Disclosure

P. Cornes: PC: Honoraria from Accord Healthcare, Amgen, Bernstein, BMJ, European Generics Association, Global Academy of Health Sciences, Hospira/Pfizer, Janssen, Lilly, Merck Serono, Napp, National Cancer Society Malaysia, PhAMA, Roche, Sandoz, Teva. A. Krendyukov: Employee of Hexal AG, Holzkirchen, Germany.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.